Strides Arcolab gets USFDA nod for generic skin disease cream

Drug firm Strides Arcolab has received approval from the US health regulator to market its generic Imiquimod cream, used in treating skin diseases, in the American market.

The Bangalore-based company has received approval from the US Food and Drug Administration (USFDA) for Imiquimod cream, Strides Arcolab Ltd said in a statement.

"This is the first product approval from Beltapharm, the company's USFDA approved semi-solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market," it added.

According to IMS data, the US market for generic Imiquimod cream is around USD 140 million.

Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (precancerous skin lesions) on the face or scalp, external genital and perianal warts in patients aged 12 years and more.

Strides shares were trading at Rs 624.75 apiece on the BSE, up 3.46 per cent from its previous close.


  • With IT firms pursuing independent business models, Infosys is no longer a bellwether

    The earnings season kicked off on Monday with technology major Infosys announcing its second quarter results that were more or less on expected lines


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Taslima Nasreen

Saudi Arabia will never be shamed

The health minister of Saudi Arabia Khalid Al-Falih has purportedlysaid ...

Kuruvilla Pandikattu

Our mood effects our walking style

Our mood can affect how we walk. We walk lazy ...

Dharmendra Khandal

Use technology wisely to save earth's treasures

Wildlife biologists are certainly getting inspired by our armed forces’ ...


William D. Green

Chairman & CEO, Accenture